- International Antitrust
- Private Equity
- Class Actions
- Mergers & Acquisitions / Premerger Notification
- General Counseling & Distribution
- Government & Private Antitrust Litigation & Investigations
- EU Competition Law
- Regulated Industries
- Private Equity M&A
- Life Sciences
- Financial Services
- Life Sciences and Healthcare
Named a Class Actions and Mass Torts 'Powerhouse' in BTI's Litigation Outlook 2014 report
honors + affiliations
Member, American Bar Association, Antitrust Section
Executive Member, New York State Antitrust Bar Committee
Former Member, Association of the Bar of the City of New York, Antitrust and Trade Regulation Committee
Listed, Chambers USA: America's Leading Lawyers for Business (2010–2014)
Listed, Global Competition Review's International Who's Who of Competition Lawyers & Economists (2013)
- New York
- U.S. Court of Appeals for the Second Circuit
- U.S. District Court for the Southern District of New York
- New York
101 Park Avenue
New York, NY 10178-0060
Harry T. Robins is a partner in Morgan Lewis's Antitrust Practice. Mr. Robins represents clients, including a number of prominent private equity firms and Fortune 500 companies, before the U.S. Federal Trade Commission and the U.S. Department of Justice, as well as international regulatory agencies, in connection with mergers and acquisitions and joint venture transactions. Mr. Robins also handles litigation and counseling matters, including class action litigation and government investigations.
Mr. Robins has had leadership roles in obtaining antitrust approvals in a number of complex transactions, including:
- On behalf of Merck & Co., Inc. in connection with its $2 billion collaboration with Bayer AG (Federal Trade Commission)
- On behalf of Pfizer Inc. in connection with its $360 million acquisition of InnoPharma, Inc. (Federal Trade Commission)
- On behalf of Cargill, Inc. in connection with its joint venture with ConAgra to form flour miller Ardent Mills (Department of Justice)
- On behalf of Perrigo Company in connection with its $160 million acquisition of Velcera, Inc. (Federal Trade Commission)
- On behalf of Pearson plc in connection with its joint venture of Penguin and Random House (Bertelsmann) (Department of Justice)
- On behalf of General Cable in connection with its acquisition of Alcan Cable from Rio Tinto (Department of Justice)
- On behalf of Apollo Management, L.P./ Berry Plastics Corporation in connection with its acquisition of Rexam SBC, specialty and beverage closures business (Department of Justice)
- On behalf of Perrigo Inc. in connection with its acquisition of Paddock Laboratories (Federal Trade Commission)
- On behalf of Pfizer Inc. in connection with its $4 billion acquisition of King Pharmaceuticals (Federal Trade Commission)
- On behalf of Pfizer Inc. in connection with its $68 billion acquisition of Wyeth (Federal Trade Commission). Negotiated Consent Order that required no divestiture of any human health product.
- On behalf of Pearson plc in connection with its acquisition of Harcourt Assessment from Reed Elsevier (Department of Justice). Negotiated Consent Order that included product divestitures of less than 1% of Harcourt's gross revenue worldwide.
- On behalf of Owens Corning in connection of its acquisition of St. Gobain's glass composite business (Multi-jurisdictional approvals)
- On behalf of Progress Rail (formerly owned by One equity Partners) in connection with its sale of its FM Industries business to Amsted, Inc. (Department of Justice)
- On behalf of Performance Fibers' (Sun Capital) acquisition of Invista's European fiber business (Phase II investigation by the German Federal Cartel Office)
- On behalf of One Equity Partners (the private equity arm of JP Morgan Chase) in the United States and the European Union in connection with One Equity Partners' sale of Moneyline Telerate to Reuters plc.
Mr. Robins represented HSBC in connection with the foreign currency exchange class action litigation (S.D.N.Y.), and Tolko Industries in connection with the oriented strand board class action litigation (E.D. Pa). Additionally, Mr. Robins negotiated a settlement on behalf of HSBC in a multi-defendant antitrust case that avoided any payment for damages. He was also instrumental in winning a motion to dismiss a complex tying claim involving two medical device companies (S.D.N.Y.).
Mr. Robins is often quoted with respect to issues pertaining to the Hart-Scott-Rodino Act. Most recently, he discussed FTC's proposed changes to Hart-Scott-Rodino premerger rules in Compliance Week's article "Changes Good and Bad Coming to HSR Compliance" as well as in the article "New Merger Rules: Boon or Bane?" featured in CFO. Mr. Robins is also a frequent writer and speaker on antitrust matters. His most recent speaking engagement includes a panel presentation on “Price Maintenance after Visa/Mastercard” during Canadian Bar Association’s 2013 Competition Spring Forum. He also has presented at the ABA Business Law Section on "Proposed Changes to the Hart-Scott-Rodino Act Rules," and in 2011, presented "Mergers—Nuts & Bolts, Distribution Practices & Competitor Collaborations in the United States: Spotting the Issues for Business Lawyers" at the ABA's Annual meeting in Toronto.
Mr. Robins is admitted to practice in New York and Connecticut and before the U.S. Court of Appeals for the Second Circuit and the U.S. District Court for the Southern District of New York.
- American University, Washington College of Law, 1996, J.D., With Honors
- Columbia College, Columbia University, 1990, B.A.